Cargando…
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles
BACKGROUND: Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. In contrast to inhibitors that target the active site of the viral protease, bevirimat specifically inhibits a single cl...
Autores principales: | Nguyen, Albert T, Feasley, Christa L, Jackson, Ken W, Nitz, Theodore J, Salzwedel, Karl, Air, Gillian M, Sakalian, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267693/ https://www.ncbi.nlm.nih.gov/pubmed/22151792 http://dx.doi.org/10.1186/1742-4690-8-101 |
Ejemplares similares
-
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat
por: Adamson, Catherine S, et al.
Publicado: (2010) -
Preservation
of HIV-1 Gag Helical Bundle Symmetry
by Bevirimat Is Central to Maturation Inhibition
por: Pak, Alexander J., et al.
Publicado: (2021) -
Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
por: Allaway, Graham P
Publicado: (2006) -
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
por: Fun, Axel, et al.
Publicado: (2011) -
Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice
por: Stoddart, Cheryl A., et al.
Publicado: (2007)